Profil
Paul McInulty is currently the Senior Vice President-Regulatory Affairs at Arvinas, Inc. Prior to this, he worked as the Vice President-Therapeutic Head & Hematology at Bristol Myers Squibb Co. and as the Vice President-Regulatory Affairs at Celgene Corp.
He completed his undergraduate degree at The University of Sheffield.
Postes actifs de Paul McInulty
Sociétés | Poste | Début |
---|---|---|
ARVINAS, INC. | General Counsel | 03/10/2022 |
Anciens postes connus de Paul McInulty
Sociétés | Poste | Fin |
---|---|---|
CELGENE | General Counsel | - |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formation de Paul McInulty
The University of Sheffield | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ARVINAS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |